GlaxoSmithKline (ticker: GSK) shares paired prior gains and fell 0.6% after agreeing to pay CureVac as much as £866 million, in a deal that nets the U.K. pharmaceutical giant a nearly 10% stake in the German biotech known for its vaccines capabilities.Write to Steve Goldstein at sgoldstein@marketwatch.com, Teresa Rivas at teresa.rivas@barrons.com and Ben Levisohn at Ben.Levisohn@barrons.com Global stocks ended mostly higher on Monday, even as talks dragged on a key European Union leaders’ summit and as a wave of earnings is set for release.